References

1. Mayer L, Eisenhardt D. Lack of induction of suppressor T-cells by intestinal epi- thelial cells from patients with inflammatory bowel disease. J Clin Invest 1990; 86:1255-1260.
2. Saxon A, Shanahan F, Landers C, Ganz T, Targan S. A distinct subset of antineutrophil cytoplasmic antibodies is associated with inflammatory bowel dis- ease. J Allergy Clin Immunol 1990; 86:202-210.
3. Gitnick G. Etiology of inflammatory bowel disease: Where have we been? Where are we going? Scand J Gastroenterol 1990; 25(Suppl 175):93-96.
4. Das KM, Vecchi M, Sakamaki S. A shared and unique epitope(s) on human colon, skin, and biliary epithelium detected by a monoclonal antibody. Gastroenterology 1990; 98:464-469.
5. Seldenrijk CA, Drexhage HA, Meuwissen SG, Meijer CJ. T-cellular immune reactions (in macrophage inhibition factor assay) against Mycobacterium paratuberculosis, Mycobacterium kansasii, Mycobacterium tuberculosis, Mycobacterium avium in patients with chronic inflammatory bowel disease. Gut 1990; 31:529-535.
6. Katz KD, Hollander D, Vadheim CM, et al. Intestinal permeability in patients with Crohn's disease and their healthy relatives. Gastroenterology 1989; 97:927-931.
7. Modigliani R, Mary YJ, Simon JF, et al. Clinical, biological, and endoscopic pic- ture of attacks of Crohn's disease: evolution on prednisolone. Gastroenterology 1990; 98:811-818.
8. International Mesalazine Study Group. Coated oral 5-aminosalicylic acid versus placebo in maintaining remission of inactive Crohn's disease. Aliment Pharmacol Ther 1990; 4:55-64.
9. Present DH. 6-Mercaptopurine and other immunosuppressive agents in the treatment of Crohn's disease and ulcerative colitis. Gastroenterol Clin North Am 1989; 18:57-71.
10. Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111:641-649.
11. Brynskov J, Freund L, Rasmussen SN, et al. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. N Engl J Med 1989; 321:845-850.
12. Fedorak RN, Empey LR, MacArthur C, Jewell LD. Misoprostol provides a colonic mucosal protective effect during acetic acid-induced colitis in rats. Gastroenterology 1990; 98:615-625.
13. Wallace JL, Keenan CM. An orally active inhibitor of leukotriene synthesis accelerates healing in a rat model of colitis. Am J Physiol 1990; 258:G527-534.
14. Salomon P, Kornbluth AA, Janowitz HD. Treatment of ulcerative colitis with fish oil n-3-omega-fatty acid: an open trial. J Clin Gastroenterol 1990; 12:157-161.
15. Campieri M, De Franchis R, Bianchi Porro G, Ranzi T, Brunetti G, Barbara L. Mesalazine (5-aminosalicylic acid) suppositories in the treatment of ulcerative proctitis or distal proctosigmoiditis: a randomized controlled trial. Scand J Gastroenterol 1990; 25:663-668.
16. Campieri M, Gionchetti P, Belluzzi A, et al. Topical treatment with 5-aminosali- cylic in distal ulcerative colitis by using a new suppository preparation: a double-blind placebo controlled trial. Int J Colorectal Dis 1990; 5:79-81.
17. Riley SA, Turnberg LA. Sulphasalazine and the aminosalicylates in the treatment of inflammatory bowel disease. Q J Med 1990; 75:551-562.
18. Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989; 110:353-356.